LEA3D: A computer-aided ligand design for structure-based drug design

Journal of Medicinal Chemistry

Volumn 48, Issue 7, 2005, Pages 2457-2468

  Douguet, Dominique ^a   Munier Lehmann, Hélène ^b   Labesse, Gilles ^a   Pochet, Sylvie ^b  

^a INSERM   (France)

^b INSTITUT PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN; PROTEIN KINASE; RIBOSE; THYMIDYLATE KINASE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL STRUCTURE; DATA BASE; DRUG DESIGN; DRUG TARGETING; ENZYME ASSAY; ENZYME STRUCTURE; ENZYME SUBSTRATE; GENE MUTATION; GENETIC ALGORITHM; INFORMATION SYSTEM; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; QUANTITATIVE STRUCTURE ACTIVITY RELATION; SCORING SYSTEM;

ALGORITHMS; BINDING SITES; COMPUTER-AIDED DESIGN; DATABASES, FACTUAL; DRUG DESIGN; LIGANDS; MODELS, MOLECULAR; MYCOBACTERIUM TUBERCULOSIS; NUCLEOSIDE-PHOSPHATE KINASE; PROTEIN BINDING; PROTEINS; SOFTWARE;

EID: 17144419244     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0492296     Document Type: Article

References (54)

1. Cohen-Gonsaud, M.; Catherinot, V.; Labesse, G.; Douguet, D. From molecular, modeling to drug design. Practical Bioinformatics; Bujnicki, J. M., Ed.; Springer-Verlag: Berlin, 2004; pp 35-72.
2. Venkatasubramanian, V.; Chan, K.; Caruthers, J. M. Evolutionary Design of Molecules with Desired Properties Using the Genetic Algorithm. J. Chem. Inf. Comput. Sci. 1995, 35, 188-195.
3. Parrill, A. L. Evolutionary and genetic methods in drug design. Drug Discovery Today 1996, 1, 514-521.
4. Schneider, G.; Bohm, H. J. Virtual screening and fast automated docking methods. Drug Discovery Today 2002, 7, 64-70.
5. Honma, T. Recent advances in de novo design strategy for practical lead identification. Med. Res. Rev. 2003, 23, 606-632.
6. Ooms, F. Molecular modeling and computer aided drug design. Examples of their applications in medicinal chemistry. Curr. Med. Chem. 2000, 7, 141-158.
7. Schneider, G.; Schrodl, W.; Wallukat, G.; Muller, J.; Nissen, E.; et al. Peptide design by artificial neural networks and computer-based evolutionary search. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 12179-12184.
8. Schneider, G.; Lee, M. L.; Stahl, M.; Schneider, P. De novo design of molecular architectures by evolutionary assembly of drug-derived building blocks. J. Comput.-Aided Mol. Des. 2000, 14, 487-494.
9. Babine, R. E.; Bleckman, T. M.; Kissinger, C. R.; Showalter, R.; Pelletier, L. A.; et al. Design, synthesis and X-ray crystallographic studies of novel FKBP-12 ligands. Bioorg. Med. Chem. Lett. 1995, 3, 1719-1724.
10. Nishibata, Y.; Itai, A. Automatic creation of drug candidate structures based on receptor structure. Starting point for artificial lead generation. Tetrahedron 1991, 47, 8885-8990.
11. Bohm, H. J. The computer program LUDI: A new method for the de novo design of enzyme inhibitors. J. Comput.-Aided Mol. Des. 1992, 6, 61-78.
12. Gillet, V.; Johnson, A. P.; Mata, P.; Sike, S.; Williams, P. SPROUT: A program for structure generation. J. Comput.-Aided Mol. Des. 1993, 7, 127-153.
13. Eísen, M. B.; Wiley, D. C.; Karplus, M.; Hubbard, R. E. HOOK: A program for finding novel molecular architectures that satisfy the chemical and steric requirements of a macromolecule binding site. Proteins 1994, 19, 199-221.
14. Bohacek, R. S.; McMartin, C. Multiple highly diverse structures complementary to enzyme binding sites: Results of extensive application of de novo design method incorporating combinatorial growth. J. Am. Chem. Soc. 1994, 116, 5560-5571.
15. Clark, D. E.; Frenkel, D.; Levy, S. A.; Li, J.; Murray, C. W.; et al. PRO-LIGAND: An approach to de novo molecular design. 1. Application to the design of organic molecules. J. Comput.-Aided Mol. Des. 1995, 9, 13-32.
16. Pearlman, D. A.; Murcko, M. A. CONCERTS: Dynamic connection of fragments as an approach to de novo ligand design. J. Med. Chem. 1996, 39, 1651-1663.
17. LeapFrog, 6.8 ed.; Tripos, Inc.: St Louis, MO.
18. Pegg, S. C.; Haresco, J. J.; Kuntz, I. D. A genetic algorithm for structure-based de novo design. J. Comput.-Aided Mol. Des. 2001, 15, 911-933.
19. Wang, R.; Gao, Y.; Lai, L. A Multi-Purpose Program for Structure-Based Drug Design. J. Mol. Model. 2000, 6, 498-516.
20. Blaney, J. M.; Dixon, J. S.; Weininger, D. Molecular Graphics Society Meeting on Binding Sites: Characterising and Satisfying Steric and Chemical Restraints; U.K., 1993.
21. Venkatasubramanian, V.; Chan, K.; Caruthers, J. M. Computer Aided Molecular Design Using Genetic Algorithms. Comput. Chem. Eng. 1994, 18, 833-844.
22. Douguet, D.; Thoreau, E.; Grassy, G. A genetic algorithm for the automated generation of small organic molecules: Drug design using an evolutionary algorithm. J. Comput.-Aided Mol. Des. 2000, 14, 449-466.
23. Weininger, D. SMILES. 3. depict: Graphical depiction of chemical structures. J. Chem. Inf. Comput. Sci. 1990, 30, 237-243.
24. Breinbauer, R.; Vetter, I. R.; Waldmann, H. From protein domains to drug candidates-natural products as guiding principles in the design and synthesis of compound libraries. Angew. Chem. Int. Ed. 2002, 41, 2879-2890.
25. Cragg, C. M.; Newman, D. J.; Snader, K. M. For an outstanding analysis of the role of natural products in pharmaceuticals. J. Nat. Prod. 1997, 60, 52-60.
26. Bohacek, R. S.; McMartin, C.; Guida, W. C. The art and practice of structure-based drug design: A molecular modeling perspective. Med. Res. Rev. 1996, 16, 3-50.
27. Rarey, M.; Wefing, S.; Lengauer, T. Placement of medium-sized molecular fragments into active sites of proteins. J. Comput.-Aided Mol. Des. 1996, 10, 41-54.
28. Holland, J. Adaptation in natural and artificial systems; University of Michigan Press: Ann Arbor, MI, 1976.
29. Murray, A.; Louis, S. J. Design strategies for evolutionary robots. Proceedings of the Third Golden West International Conference on Intelligent Systems; Kluwer Academic Press: Norwell, MA, 1995; pp 609-616.
30. Forrest, S. Genetic Algorithms: Principles of Natural Selection Applied to Computation. Science 1993, 261, 872-878.
31. Goldberg, D. E. Genetic Algorithms in Search, Optimization, and Machine Learning; Addison-Wesley: Reading, MA, 1989.
32. Fogel, L. J.; Owens, A. J.; Walsh, M. J. Artificial Intelligence through Simulated Evolution; John Wiley & Sons: New York, 1966.
33. Lepre, C. A.; Peng, J.; Fejzo, J.; Abdul-Manan, N.; Pocas, J.; et al. Applications of SHAPES screening in drug discovery. Comb. Chem. High Throughput Screen 2002, 5, 583-590.
34. Gasteiger, J.; Rudolph, C.; Sadowski, J. Automatic Generation of 3D-Atomic Coordinates for Organic Molecules. Tetrahedron Comput. Method 1990, 3, 537-547.
35. Rockey, W. M.; Elcock, A. H. Progress toward virtual screening for drug side effects. Proteins 2002, 48, 664-671.
36. De Jong, K. A. An Analysis of the Behavior of a Class of Genetic Adaptive Systems. In Department Computer and Communication Sciences; University of Michigan: Ann Arbor, MI, 1975.
37. Li de la Sierra, I.; Munier-Lehmann, H.; Gilles, A. M.; Barzu, O.; Delarue, M. X-ray structure of TMP kinase from Mycobacterium tuberculosis complexed with TMP at 1.95 A resolution. J. Mol. Biol. 2001, 311, 87-100.
38. Pochet, S.; Dugue, L.; Douguet, D.; Labesse, G.; Munier-Lehmann, H. Nucleoside Analogues as Inhibitors of Thymidylate Kinases: Possible Therapeutical Applications. ChemBioChem 2002, 3, 108-110.
39. Van Rompaey, P.; Nauwelaerts, K.; Vanheusden, V.; Rozenski, J.; Munier-Lehmann, H.; et al. Mycobacterium tuberculosis Thymidine Monophosphate Kinase Inhibitors: Biological Evaluation and Conformational Analysis of 2′- and 3′-Modified Thymidine Analogues. Eur. J. Org. Chem. 2003, 2911-2918.
40. Vanheusden, V.; Munier-Lehmann, H.; Froeyen, M.; Dugue, L.; Heyerick, A.; et al. 3′-C-branched-chain-substituted nucleosides and nucleotides as potent inhibitors of Mycobacterium tuberculosis thymidine monophosphate kinase. J. Med. Chem. 2003, 46, 3811-3821.
41. Vanheusden, V.; Munier-Lehmann, H.; Pochet, S.; Herdewijn, P.; Van Calenbergh, S. Synthesis and evaluation of thymidine-5′〈O- monophosphate analogues as inhibitors of Mycobacterium tuberculosis thymidylate kinase. Bioorg. Med. Chem. Lett. 2002, 12, 2695-2698.
42. Munier-Lehmann, H.; Pochet, S.; Dugue, L.; Dutruel, O.; Labesse, G.; et al. Design of Mycobacterium tuberculosis thymidine monophosphate kinase inhibitors. Nucleosides Nucleotides Nucleic Acids 2003, 22, 801-804.
43. Munier-Lehmann, H.; Chaffotte, A.; Pochet, S.; Labesse, G. Thymidylate kinase of Mycobacterium tuberculosis: A chimera sharing properties common to eukaryotic and bacterial enzymes. Protein Sci 2001, 10, 1195-1205.
44. Haouz, A.; Vanheusden, V.; Munier-Lehmann, H.; Froeyen, M.; Herdewijn, P.; et al. Enzymatic and structural analysis of inhibitors designed against Mycobacterium tuberculosis thymidylate kinase. New insights into the phosphoryl transfer mechanism. J. Biol. Chem. 2003, 278, 4963-4971.
45. Fioravanti, E.; Haouz, A.; Ursby, T.; Munier-Lehmann, H.; Delarue, M. et al. Mycobacterium tuberculosis thymidylate kinase: Structural studies of intermediates along the reaction pathway. J. Mol. Biol. 2003, 327, 1077-1092.
46. Pochet, S.; Dugue, L.; Labesse, G.; Delepierre, M.; Munier-Lehmann, H. Comparative study of purine and pyrimidine nucleoside analogues acting on the thymidylate kinases of Mycobacterium tuberculosis and of humans. Chembiochem 2003, 4, 742-747.
47. Ostermann, N.; Segura-Pena, D.; Meier, C.; Veit, T.; Monnerjahn, C.; et al. Structures of human thymidylate kinase in complex with prodrugs: Implications for the structure-based design of novel compounds. Biochemistry 2003, 42, 2568-2577.
48. Bissantz, C.; Folkers, G.; Rognan, D. Protein-based virtual screening of chemical databases. 1. Evaluation of different docking/scoring combinations. J Med Chem 2000, 43, 4759-4767.
49. Schulz-Gasch, T.; Stahl, M. Binding site characteristics in structure-based virtual screening: Evaluation of current docking tools. J. Mol. Model (Online) 2003, 9, 47-57.
50. Kontoyianni, M.; McClellan, L. M.; Sokol, G. S. Evaluation of docking performance: Comparative data on docking algorithms. J. Med. Chem. 2004, 47, 558-565.
51. Brooks, B. R.; Bruccoleri, R. E.; Olafson, B. D.; States, D. J.; Swaminathan, S.; et al. CHARMM: A program for macromolecular energy, minimization, and dynamics calculations. J. Comput. Chem. 1983, 4, 187-217.
52. Eisenhaber, F.; Argos, P. Improved strategy in analytic surface calculation for molecular systems: Handling singularities and computational efficiency. J. Comput. Chem. 1993, 11, 1272-1280.
53. Viswanadhan, V. N.; Ghose, A. K.; Revankar, G. R.; Robins, R. K. Atomic Physicochemical Parameters for Three-Dimensional Structure Directed Quantitative Structure-Activity Relationships. J. Chem. Inf. Comput. Sci. 1989, 29, 163-172.
54. Blondin, C.; Serina, L.; Wiesmuller, L.; Gilles, A. M.; Barzu, O. Improved spectrophotometric assay of nucleoside monophosphate kinase activity using the pyruvate kinase/lactate dehydrogenase coupling system. Anal. Biochem 1994, 22.